
Opinion|Videos|November 27, 2024
Managing Treatment Challenges in HER2-Directed Therapies
Key Takeaways
- Understanding molecular mechanisms of resistance is crucial for developing novel therapeutic agents and combination strategies in HER2-directed therapies.
- Personalized medicine, utilizing genomic profiling, is expected to tailor treatments to individual patient profiles, enhancing efficacy.
An exploration of emerging strategies to overcome resistance to HER2-directed therapies based on ongoing research advancements.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How might strategies to address resistance to HER2-directed therapies evolve with ongoing research?
Advertisement
Related to this article

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
2
Ribupatide Yields Up to 17.7% Weight Loss in Phase 3 GEMINI-1 Trial
3
GLP-1s Alone Won't Solve Obesity, JAMA Summit Report Says
4
Menopause Benefit Design Should Prioritize Access, Total Cost of Care
5


